Between the beginning of January 2020 and June 14, 2023, of the 1,134,641 deaths caused by COVID-19 in the United States, around 307,169 had occurred among those aged 85 years and older. This statistic shows the number of coronavirus disease 2019 (COVID-19) deaths in the U.S. from January 2020 to June 2023, by age.

As of April 26, 2023, around 27 percent of total COVID-19 deaths in the United States have been among adults 85 years and older, despite this age group only accounting for two percent of the U.S. population. This statistic depicts the distribution of total COVID-19 deaths in the United States as of April 26, 2023, by age group.

In 2020, there were around 872 deaths per 100,000 population among those aged 65 years and older in New Jersey due to COVID-19. The COVID-19 death rate in Hawaii was significantly lower at around 90 deaths per 100,000 population. This statistic illustrates the death rates due to COVID-19 among adults aged 65 and over in the United States in 2020, by state.

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov.

Deaths involving COVID-19, pneumonia, and influenza reported to NCHS by sex, age group, and jurisdiction of occurrence.

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases

Provisional deaths registration data for single year of age and average age of death (median and mean) of persons whose death involved coronavirus (COVID-19), England and Wales. Includes deaths due to COVID-19 and breakdowns by sex.

The spread of coronavirus (COVID-19) in Italy has not hit uniformly people of every age, as about 60 percent of the individuals infected with the virus were under 50 years old. However, deaths occurred mostly among the elderly. The virus has claimed approximately 190 thousand lives, but, as the chart shows, roughly 85 percent of the victims were older people, aged 70 years or more. People between 80 and 89 years were the most affected, with roughly 76 thousand deaths within this age group.

Number of total cases Since the first case was detected, coronavirus has spread quickly across Italy. As of April 2023, authorities have reported over 25.8 million cases in the country. This figure includes the deceased, the recovered, and current active cases. COVID recoveries represent the vast majority, reaching approximately 25.5 million.

Regional differences In terms of COVID cases, Lombardy has been the hardest hit region, followed by the regions of Campania, and Veneto. Likewise, in terms of deaths, Lombardy was the region with the highest number, with roughly 46 thousand losses. On the other hand, this is also the region with the highest number of COVID-19 vaccine administered doses, with a figure of approximately 25.5 million.

For a global overview visit Statista's webpage exclusively dedicated to coronavirus, its development, and its impact.

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases

COVID-19 causes significant mortality in elderly and vulnerable people and spreads easily in care homes where one in seven individuals aged > 85 years live. However, there is no surveillance for infection in care homes, nor are there systems (or research studies) monitoring the impact of the pandemic on individuals or systems. Usual practices are disrupted during the pandemic, and care home staff are taking on new and unfamiliar roles, such as advanced care planning. Understanding the nature of these changes is critical to mitigate the impact of COVID-19 on residents, relatives and staff. 20 care homes staff members were interviewed using semi-structured interviews.

The COVID-19 pandemic poses a substantial risk to elderly and vulnerable care home residents and COVID-19 can spread rapidly in care homes. We have national, daily data on people with COVID-19 and deaths, but there is no similar data for care homes. This makes it difficult to know the scale of the problem, and plan how to keep care home residents safe. We also want to understand the impact of COVID-19 on care home staff and residents. Researchers from University College London (UCL) will measure the number of cases of COVID-19 in care homes, using data from Four Seasons Healthcare, a large care home chain. FSHC remove residents' names and addresses before sending the dataset to UCL, protecting resident's confidentiality. Since we cannot visit care homes during the pandemic, we will hold virtual (online) discussion meetings with care home stakeholders (staff, residents, relatives, General Practice teams) every 6-8 weeks, to learn rapid lessons about managing COVID-19 in care homes and identify pragmatic solutions. Our findings will be shared with FHSC, GPs and Public Health England, patients and the public, and support the national response to COVID-19. Patients and the public will be involved in all stages of the research.

The coronavirus disease (COVID-19) pandemic has had unprecedented consequences for Canada's aging population with the majority of COVID-19 deaths (approximately 80% during 2020) occurring among adults aged 65 years and older. Both advanced age and underlying chronic diseases and conditions contribute to these severe outcomes. Excess mortality refers to additional mortality above the expected level (based on mortality in the same period in the preceding year or averaged over several preceding years in the same population). This measure allows for the measurement of death directly and indirectly related to COVID-19 and provides a summary measure of its whole system impact in addition to its impact on mortality.

It was estimated that around 30 percent of those aged 80 years and older who had COVID-19 in the United States from January 22 to May 30, 2020 died from the disease. Deaths due to COVID-19 are much higher among those with underlying health conditions such as cardiovascular disease, chronic lung disease, or diabetes. This statistic shows the percentage of people in the U.S. who had COVID-19 from January 22 to May 30, 2020 who died, by age.

For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

Actions of Public Health France

Public Health France’s mission is to improve and protect the health of populations. During the health crisis linked to the COVID-19 outbreak, Santé publique France is responsible for monitoring and understanding the dynamics of the epidemic, anticipating the various scenarios and putting in place actions to prevent and limit the transmission of this virus on national territory.

The Tracking Information System (SI-DEP)

The new screening information system (SI-DEP), which has been in operation since 13 May 2020, is a secure platform where the results of the laboratory tests carried out by all city and hospital laboratories for SARS-COV2 are systematically recorded.

The creation of this information system is authorised for a period of 6 months from the end of the state of health emergency by application of Decree No 2020-551 of 12 May 2020 on the information systems referred to in Article 11 of Law No 2020-546 of 11 May 2020 extending the state of health emergency and supplementing its provisions.

Description of data

This dataset provides information at the departmental and regional level: — the daily and weekly incidence rate per age group; — the daily and weekly standardised incidence rate; — the sliding standardised incidence rate.

This dataset provides information at the national level: — the daily and weekly incidence rate by age group and sex; — the daily and weekly standardised incidence rate; — the sliding standardised incidence rate.

The incidence rate corresponds to the number of positive tests per 100,000 inhabitants. It shall be calculated as follows: (100000 * number of positive cases)/Population

Accuracy: — From 29/08 onwards, laboratory data indicators (SI-DEP) show rates of incidence, positivity and screening adjusted for screenings conducted at airports upon arrival of international flights. — For more information, see the methodological note available in the resources. Limits: — Only the biological tests of persons for whom the residence department could be located are shown on the maps. Persons whose department could not be traced in the SIDEP data are counted only at the whole French level. As a result, the sum of the tests indicated in the departments or regions is less than the number of tests indicated in France. — The time limit for repeating tests may exceed 9 days in some cases. The indicators are adjusted daily according to the receipt of the results.

Notable changes

Since 8 December, after verifying the quality of the reported data, all results of RT-PCR or Antigenic tests have been included in the production of national and territorial epidemiological indicators (incidence rates, positivity rates and screening rates) relevant to the monitoring of the COVID-19 outbreak. On the other hand, the epidemic is prolonging in time and screening capacities have increased, leading to an increasing frequency of people tested several times. Thus, an adjustment of the methods of splitting for patients benefiting from repeated tests and therefore the definition of the persons tested was necessary. Public Health France, in its patient-centred epidemiological approach, has therefore adapted its methods to ensure that these indicators reflect, in particular, the proportion of infected people among the population tested. These developments have no impact on the trends and interpretation of the dynamics of the epidemic, which remain the same. More precise test data (impact and positivity) are also published by Santé publique France (SI-DEP data).

During the first two year of the Covid-19 pandemic, deaths tolls differed from a country to another. In a previous research work on 39 countries, we have found that some population’s characteristics were either negatively (birth rate/mortality rate, fertility rate) or positively (cancer score, Alzheimer disease score, percent of people above 65 years old, levels of alcohol intake) correlated with Covid-19 mortality. We also found that low levels of climate factors (average annual temperature, average hours of sunshine, average annual level of UV index) were positively correlated with Covid-19 deaths numbers as well. In the present study, we have developped an anti-Covid Capacity index that takes into account all the above mentioned parameters. The polynomial analysis of the anti-Covid Capacity and its corresponding geographic latitude of each country has generated a bell-shaped curve, with a high coefficient of determination (R2= 0.78). Lower anti-Covid capacity values were recorded in countries of low and high latitudes, respectively. Instead, plotting covid-19 deaths numbers against geographic latitude levels has generated an inverted bell-shaped curve, with higher deaths numbers at low and high latitudes, respectively. The analysis by a simple linear regression has shown that Covid-19 deaths numbers were significantly (p= 2,40 x 10-9) and negatively correlated to the anti-Covid Capacity index values. Our data demonstrate that the negative prepandemic human conditions, and the low scores of both annual temperature and UV index in many countries were the key factors behind high Covid-19 mortality, and they can be expressed as a simple index of anti-Covid capacity of a country that can predict the death-associated severity of Covid-19 disease, and thus, according to a country’s geographic latitude.

Background: The older population is often disproportionately and adversely affected during humanitarian emergencies, as has also been seen during the COVID-19 pandemic. Data regarding COVID-19 in older adults is usually over-generalised and does not delve into details of the clinical characteristics in them. This study was conducted to analyse clinical and laboratory characteristics, risk factors, and complications of COVID-19 between older adults who survived and those who did not.

Methods: We conducted a case-control study among older adults(age > 60 years) admitted to the Intensive Care Unit(ICU) during the COVID-19 pandemic. The non-survivors (cases) were matched with age and sex-matched survivors (control) in a ratio of 1: 3. The data regarding socio-demographics, clinical characteristics, complications, treatment, laboratory data, and outcomes were analysed.

Results: The most common signs and symptoms observed were fever (cases vs controls) (68.92 vs. 68.8%), followed by shortness of breath (62.2% Vs. 52.2%), and cough (47.3% Vs. 60.2%). Our analysis found no association between the presence of any of the comorbidities and mortality. At admission, laboratory markers such as LDH(Lactate Dehydrogenase), WBC(White Blood Count), creatinine, CRP(C-Reactive Protein), D-dimer, ferritin, and IL-6(Interleukin-6) were found to be significantly higher among the cases than among the controls. Complications such as development of seizure, bacteremia, acute renal injury, respiratory failure, and septic shock were seen to have a significant association with non-survivors.

Conclusions: Hypoxia, tachycardia, and tachypnoea at presentation were associated with higher mortality. The older adults in this study mostly presented with the typical clinical features of COVID-19 pneumonia. The presence of comorbid illnesses among them did not affect mortality. Higher death was seen among those with higher levels of CRP, LDH, D-dimer, and ferritin; and with lower lymphocyte counts.

Analysis of ‘COVID-19 Cases by Population Characteristics Over Time’ provided by Analyst-2 (analyst-2.ai), based on source dataset retrieved from https://catalog.data.gov/dataset/a3291d85-0076-43c5-a59c-df49480cdc6d on 13 February 2022.

--- Dataset description provided by original source is as follows ---

Note: On January 22, 2022, system updates to improve the timeliness and accuracy of San Francisco COVID-19 cases and deaths data were implemented. You might see some fluctuations in historic data as a result of this change. Due to the changes, starting on January 22, 2022, the number of new cases reported daily will be higher than under the old system as cases that would have taken longer to process will be reported earlier.

A. SUMMARY This dataset shows San Francisco COVID-19 cases by population characteristics and by specimen collection date. Cases are included on the date the positive test was collected.

Population characteristics are subgroups, or demographic cross-sections, like age, race, or gender. The City tracks how cases have been distributed among different subgroups. This information can reveal trends and disparities among groups.

Data is lagged by five days, meaning the most recent specimen collection date included is 5 days prior to today. Tests take time to process and report, so more recent data is less reliable.

B. HOW THE DATASET IS CREATED Data on the population characteristics of COVID-19 cases and deaths are from: * Case interviews * Laboratories * Medical providers

These multiple streams of data are merged, deduplicated, and undergo data verification processes. This data may not be immediately available for recently reported cases because of the time needed to process tests and validate cases. Daily case totals on previous days may increase or decrease. Learn more.

Data are continually updated to maximize completeness of information and reporting on San Francisco residents with COVID-19.

Data notes on each population characteristic type is listed below.

Race/ethnicity * We include all race/ethnicity categories that are collected for COVID-19 cases. * The population estimates for the "Other" or “Multi-racial” groups should be considered with caution. The Census definition is likely not exactly aligned with how the City collects this data. For that reason, we do not recommend calculating population rates for these groups.

Sexual orientation * Sexual orientation data is collected from individuals who are 18 years old or older. These individuals can choose whether to provide this information during case interviews. Learn more about our data collection guidelines. * The City began asking for this information on April 28, 2020.

Gender * The City collects information on gender identity using these guidelines.

Comorbidities * Underlying conditions are reported when a person has one or more underlying health conditions at the time of diagnosis or death.

Transmission type * Information on transmission of COVID-19 is based on case interviews with individuals who have a confirmed positive test. Individuals are asked if they have been in close contact with a known COVID-19 case. If they answer yes, transmission category is recorded as contact with a known case. If they report no contact with a known case, transmission category is recorded as community transmission. If the case is not interviewed or was not asked the question, they are counted as unknown.

Homelessness Persons are identified as homeless based on several data sources: * self-reported living situation
* the location at the time of testing * Department of Public Health homelessness and health databases * Residents in Single-Room Occupancy hotels are not included in these figures.
These methods serve as an estimate of persons experiencing homelessness. They may not meet other homelessness definitions.

Skilled Nursing Facility (SNF) occupancy * A Skilled Nursing

--- Original source retains full ownership of the source dataset ---

Objective: To study the differences in clinical characteristics, risk factors, and complications across age-groups among the inpatients with the coronavirus disease 2019 (COVID-19).Methods: In this population-based retrospective study, we included all the positive hospitalized patients with COVID-19 at Wuhan City from December 29, 2019 to April 15, 2020, during the first pandemic wave. Multivariate logistic regression analyses were used to explore the risk factors for death from COVID-19. Canonical correlation analysis (CCA) was performed to study the associations between comorbidities and complications.Results: There are 36,358 patients in the final cohort, of whom 2,492 (6.85%) died. Greater age (odds ration [OR] = 1.061 [95% CI 1.057–1.065], p < 0.001), male gender (OR = 1.726 [95% CI 1.582–1.885], p < 0.001), alcohol consumption (OR = 1.558 [95% CI 1.355–1.786], p < 0.001), smoking (OR = 1.326 [95% CI 1.055–1.652], p = 0.014), hypertension (OR = 1.175 [95% CI 1.067–1.293], p = 0.001), diabetes (OR = 1.258 [95% CI 1.118–1.413], p < 0.001), cancer (OR = 1.86 [95% CI 1.507–2.279], p < 0.001), chronic kidney disease (CKD) (OR = 1.745 [95% CI 1.427–2.12], p < 0.001), and intracerebral hemorrhage (ICH) (OR = 1.96 [95% CI 1.323–2.846], p = 0.001) were independent risk factors for death from COVID-19. Patients aged 40–80 years make up the majority of the whole patients, and them had similar risk factors with the whole patients. For patients aged

Age-standardised mortality rates for deaths involving coronavirus (COVID-19), non-COVID-19 deaths and all deaths by vaccination status, broken down by age group.

After entering Italy, coronavirus (COVID-19) has been spreading fast. An analysis of the individuals who died after contracting the virus revealed that the vast majority of deaths occurred among the elderly. As of May, 2023, roughly 85 percent were patients aged 70 years and older.

Italy's death toll was one of the most tragic in the world. In the last months, however, the country saw the end to this terrible situation: as of May 2023, roughly 84.7 percent of the total Italian population was fully vaccinated.

As of May, 2023, the total number of cases reported in the country were over 25.8 million. The North of the country was the mostly hit area, and the region with the highest number of cases was Lombardy.

For a global overview visit Statista's webpage exclusively dedicated to coronavirus, its development, and its impact.

Introduction: Older adults are more susceptible to severe COVID-19, with increased all-cause mortality. This has been attributed to their multimorbidity and disability. However, it remains to be established which clinical features of older adults are associated with severe COVID-19 and mortality. This information would aid in an accurate prognosis and appropriate care planning. Here, we aimed to identify the chronic clinical conditions and the comorbidity clusters associated with in-hospital mortality in a cohort of older COVID-19 patients who were admitted to the IRCCS Policlinico San Martino Hospital, Genoa, Italy, between January and April 2020.Methods: This was a retrospective cohort study including 219 consecutive patients aged 70 years or older and is part of the GECOVID-19 study group. During the study period, upon hospital admission, demographic information (age, sex) and underlying chronic medical conditions (multimorbidity) were recorded from the medical records at the time of COVID-19 diagnosis before any antiviral or antibiotic treatment was administered. The primary outcome measure was in-hospital mortality.Results: The vast majority of the patients (90%) were >80 years; the mean patient age was 83 ± 6.2 years, and 57.5% were men. Hypertension and cardiovascular disease, along with dementia, cerebrovascular diseases, and vascular diseases were the most prevalent clinical conditions. Multimorbidity was assessed with the Cumulative Illness Rating Scale. The risk of in-hospital mortality due to COVID-19 was higher for males, for older patients, and for patients with dementia or cerebral-vascular disease. We clustered patients into three groups based on their comorbidity pattern: the Metabolic-renal-cancer cluster, the Neurocognitive cluster and the Unspecified cluster. The Neurocognitive and Metabolic-renal-cancer clusters had a higher mortality compared with the Unspecified cluster, independent of age and sex.Conclusion: We defined patterns of comorbidity that accurately identified older adults who are at higher risk of death from COVID-19. These associations were independent of chronological age, and we suggest that the identification of comorbidity clusters that have a common pathophysiology may aid in the early assessment of COVID-19 patients with frailty to promote timely interventions that, in turn, may result in a significantly improved prognosis.

Results data for the thesis on estimating the age-, sex-, cause-specific excess mortality during the COVID-19 pandemic in Hong Kong and South Korea.Thesis abstractBackgroundFew studies used a consistent methodology and adjusted for the risk of influenza-like illness (ILI) in historical mortality trends when estimating and comparing the cause-specific excess mortality (EM) during the COVID-19 pandemic. Previous studies demonstrated that excess mortality was widely reported from CVD and among the elderly. This study aims to estimate and compare the overall, age-, sex-, and cause-specific excess mortality during the COVID-19 pandemic in Hong Kong (HK) and South Korea (SK) with consideration of the impact of ILI.MethodsIn this population-based study, we first fitted a generalized additive model to the monthly mortality data from Jan 2010 to Dec 2019 in HK and SK before the COVID-19 pandemic. Then we applied the fitted model to estimate the EM from Jan 2020 to Dec 2022. The month index was modelled with a natural cubic spline. Akaike information criterion (AIC) was used to select the number of knots for the spline and inclusion of covariates such as monthly mean temperature, absolute humidity, ILI consultation rate, and the proxy for flu activity.FindingsFrom 2020 to 2022, the EM in HK was 239.8 (95% CrI: 184.6 to 293.9) per 100,000 population. Excess mortality from respiratory diseases (RD) (ICD-10 code: J00-J99), including COVID-19 deaths coded as J98.8, was 181.3 (95% CrI: 149.9 to 210.4) per 100,000. Except for RD, the majority of the EM in HK was estimated from cardiovascular diseases (CVD) (22.4% of the overall EM), influenza and pneumonia (16.2%), ischemic heart disease (8.9%), ill-defined causes (8.6%) and senility (6.7%). No statistically significant reduced deaths were estimated among other studied causes.From 2020 to 2022, the EM in SK was 204.7 (95% CrI: 161.6 to 247.2) per 100,000 population. Of note, COVID-19 deaths in SK were not included in deaths from RD but were recorded with the codes for emergency use as U07.1 or U07.2. The majority of the EM was estimated from ill-defined causes (32.0% of the overall EM), senility (16.6%), cerebrovascular disease (6.8%) and cardiovascular diseases (6.1%). Statistically significant reduction in mortality with 95 CrI lower than zero was estimated from vascular, other and unspecified dementia (-26.9% of expected deaths), influenza and pneumonia (-20.7%), mental and behavioural disorders (-18.8%) and respiratory diseases (-7.7%).InterpretationExcluding RD in HK which includes COVID-19 deaths, the majority of the EM in HK and SK was from CVD and senility. Mortality from influenza and pneumonia was estimated to have a statistically significant increase in HK but a decrease in SK probability due to different coding practices. HK had a heavier burden of excess mortality in the elderly age group 70-79 years and 80 years or above, while SK had a heavier burden in the age group of 60-69 years. Both HK and SK have a heavier burden of excess mortality from males than females. Better triage systems for identifying high-risk people of the direct or indirect impact of the epidemic are needed to minimize preventable mortality.